FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/05/025270 [Registered on: 20/05/2020] Trial Registered Prospectively
Last Modified On: 13/05/2020
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A study to compare effect of azithromycin versus empirical treatment in acute encephalitis syndrome 
Scientific Title of Study   Effect of intravenous Azithromycin as adjunctive empirical treatment in children with acute encephalitis syndrome  
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  KUNDAN MITTAL 
Designation  SENIOR PROFESSOR 
Affiliation  PT BD SHARMA PGIMS ROHTAK 
Address  Office of Head of department of Pediatrics, ward-14, Pt B D Sharma Postgraduate Institute of Medical Sciences, Rohtak Rohtak

Rohtak
HARYANA
124001
India 
Phone    
Fax    
Email  kundanmittal@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  KUNDAN MITTAL 
Designation  SENIOR PROFESSOR 
Affiliation  PT BD SHARMA PGIMS ROHTAK 
Address  Office of Head of department of Pediatrics, ward-14, Pt B D Sharma Postgraduate Institute of Medical Sciences, Rohtak Rohtak

Rohtak
HARYANA
124001
India 
Phone    
Fax    
Email  kundanmittal@gmail.com  
 
Details of Contact Person
Public Query
 
Name  PRITI YADAV 
Designation  POST GRADUATE RESIDENT 
Affiliation  PGIMS ROHTAK 
Address  Office of Head of department of Pediatrics, ward-14, Pt B D Sharma Postgraduate Institute of Medical Sciences, Rohtak Rohtak
ROHTAK HARYANA
Rohtak
HARYANA
124001
India 
Phone  7838754501  
Fax    
Email  prityadav@gmail.com  
 
Source of Monetary or Material Support  
PT BD SHARMA POST GRADUATE INSTITUTE OF MEDICAL SCIENCES ROHTAK HARYANA-124001 
 
Primary Sponsor  
Name  KUNDAN MITTAL 
Address  Office of Head of department of Pediatrics, ward-14, Pt B D Sharma Postgraduate Institute of Medical Sciences, Rohtak Rohtak HARYANA 124001 India 
Type of Sponsor  Other [SELF] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
PRITI YADAV  Pt B D Sharma Postgraduate Institute of Medical Sciences, Rohtak   Emergency, ward-14, ward-16, PICU of department of paediatrics, Pt B D Sharma Postgraduate Institute of Medical Sciences, rohtak
Rohtak
HARYANA 
7838754501

prityadav12@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
INSTITUTIONAL ETHICAL COMMITTEE PT BD SHARMA PGIMS ROHTAK  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: G049||Encephalitis, myelitis and encephalomyelitis, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  conventional treatment that is intravenous ceftriaxone, acyclovir, vancomycin, artesunate  a. Intravenous Ceftriaxone (100 mg/kg/day in 2 divided doses) b.Intravenous Vancomycin (60 mg/kg/day in 4 divided doses) c.Intravenous acyclovir (20 mg/kg/dose every 8 hours) [To be stopped once CSF HSV PCR is negative] d. IV artesunate: 2.4-3 mg/kg once a day to be stopped if peripheral smear for malarial parasite is negative  
Intervention  Intravenous azithromycin  Intravenous Azithromycin would be given in the dose of 10mg/kg over 5 days in addition to conventional treatment  
 
Inclusion Criteria  
Age From  1.00 Year(s)
Age To  14.00 Year(s)
Gender  Both 
Details  Presence of altered mental status with at least three of the following: fever (>38 C) lasting for more than 72 hours before or after presentation; generalized or focal seizure not attributable to preexisting seizure disorder; new onset of focal neurological deficit; CSF pleocytosis> 5/cumm; abnormality of brain parenchyma on neuro imaging suggestive of encephalitis that is acute in onset or new from prior studies; abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause, coma, or inability to talk. 
 
ExclusionCriteria 
Details  - Children with prior developmental delay or intellectual disability
- Children with known renal, pulmonary, cardiac or hepatic dysfunction.
- Children with suspected inborn errors of metabolism
- Children with toxic encephalopathy or traumatic brain injury
- Children who have hemorrhagic or ischemic stroke
- Children with clinical and laboratory evidence of multi-organ dysfunction at hospital admission
- Children who have already received treatment other than conventional treatment including Azithromycin or steroids
- Children having high clinical suspicion of bacterial meningitis or TB meningitis
- Children with a contraindication to Azithromycin or albumin
- Children with known hyper coagulable state
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Proportion of children who expired (Mortality)  during hospital stay upto discharge 
 
Secondary Outcome  
Outcome  TimePoints 
1. Proportion of children with significant disability as determined by Liverpool outcome score (LOS) at discharge
2. Proportion of children with at least one serious adverse event
3. Degree of impairment in terms of International Classification of Functioning, Disability, and Health-Children and Youth Version (ICF-CY)
4. Total length of hospital stay in days  
AT TIME OF DISCHARGE 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   20/05/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   RECRUITMENT NOT STARTED 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

The eligible participants will be enrolled consecutively. A predesigned case record form will be filled. Each eligible child will be subjected to demographic details (age, gender, socioeconomic status). A detailed history will be recorded. Complete neurological examination would be performed. All eligible participants would be admitted in Pediatric Intensive Care Unit. Management of children with acute encephalitis would be as per the standard protocol. Eligible participants would be randomized into interventional group (Azithromycin plus conventional treatment) and control group (conventional treatment).

Intervention group will be given Azithromycin plus conventional treatment and in control group only conventional treatment will be given.

Intravenous Azithromycin would be given in the dose of 10mg/kg over 5 days. Adverse events if any would be managed symptomatically and recorded. Conventional empirical treatment of acute encephalitis syndrome will be as per the consensus guidelines on evaluation and management of suspected acute encephalitis in children in India.

1.      Management of seizures with anti epileptic medication.

2.      Management to decrease raised intracranial pressure:3% Nacl or Mannitol

3.      Antimicrobial protocol:

a.       Intravenous Ceftriaxone (100 mg/kg/day in 2 divided doses)

b.      Intravenous Vancomycin (60 mg/kg/day in 4 divided doses)

c.       Intravenous acyclovir (20 mg/kg/dose every 8 hours) [To be stopped once CSF HSV PCR is negative]

d.      IV artesunate: 2.4-3  mg/kg once a day to be stopped if peripheral smear for malarial parasite is negative

4.      Management of associated systemic complication as per standard PICU protocol.

 Vital signs including heart rate, respiratory rate, mean arterial pressure would be recorded at least every 6 hourly. Level of consciousness in terms of Glasgow coma score and four scores will be evaluated every 6 hourly respiratory pattern, presence of oculo cephalic reflex, pupil size and reaction, brainstem function, fundus evaluation would be recorded at-least every 12 hourly. Need for mechanical ventilation, need for inotropic support, evidence of multi-organ dysfunction would be recorded. Once the patient is hemodynamically stable and feeding has been established, the patient would be shifted to the ward. Any adverse event following drug administration would be recorded. Common adverse events that would be recorded include fever, dyspnea, vomiting, irritable, skin rash, hypotension, Malena.

Neuroimaging including MRI Brain and EEG would be performed as soon as the patient is hemodynamically stable. Blood sample would be obtained for ELISA for scrub typhus, HIV serology and for obtaining thick and thin peripheral smear for malarial parasite. Cerebrospinal fluid (CSF) [5 ml] would be obtained for testing for Japanese encephalitis using ELISA. Glasgow coma score, FOUR scores, Liverpool outcome score, ICF-CY scoring will be performed at the time of discharge.

 
Close